Puretech Health Plc Stock EBITDA
| PRTC Stock | 167.00 2.40 1.42% |
PureTech Health plc fundamentals help investors to digest information that contributes to PureTech Health's financial success or failures. It also enables traders to predict the movement of PureTech Stock. The fundamental analysis module provides a way to measure PureTech Health's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to PureTech Health stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -17.7 M | -18.6 M |
PureTech | EBITDA |
PureTech Health plc Company EBITDA Analysis
PureTech Health's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current PureTech Health EBITDA | (17.68 M) |
Most of PureTech Health's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, PureTech Health plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
PureTech Ebitda
Ebitda |
|
According to the company disclosure, PureTech Health plc reported earnings before interest,tax, depreciation and amortization of (17.68 Million). This is much lower than that of the Life Sciences Tools & Services sector and significantly lower than that of the Health Care industry. The ebitda for all United Kingdom stocks is notably higher than that of the company.
PureTech EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses PureTech Health's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of PureTech Health could also be used in its relative valuation, which is a method of valuing PureTech Health by comparing valuation metrics of similar companies.PureTech Health is currently under evaluation in ebitda category among its peers.
PureTech Fundamentals
| Return On Equity | -0.22 | ||||
| Return On Asset | -0.13 | ||||
| Operating Margin | (230.55) % | ||||
| Current Valuation | 25.36 M | ||||
| Shares Outstanding | 239.42 M | ||||
| Shares Owned By Insiders | 15.89 % | ||||
| Shares Owned By Institutions | 78.64 % | ||||
| Price To Book | 1.61 X | ||||
| Price To Sales | 854.34 X | ||||
| Revenue | 750 K | ||||
| Gross Profit | 17.39 M | ||||
| EBITDA | (17.68 M) | ||||
| Net Income | (66.63 M) | ||||
| Total Debt | 25.34 M | ||||
| Book Value Per Share | 1.32 X | ||||
| Cash Flow From Operations | (105.92 M) | ||||
| Earnings Per Share | (0.24) X | ||||
| Target Price | 547.34 | ||||
| Number Of Employees | 90 | ||||
| Beta | 0.99 | ||||
| Market Capitalization | 399.83 M | ||||
| Total Asset | 693.97 M | ||||
| Retained Earnings | 83.82 M | ||||
| Working Capital | 295.83 M | ||||
| Net Asset | 693.97 M |
About PureTech Health Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze PureTech Health plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of PureTech Health using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of PureTech Health plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for PureTech Stock Analysis
When running PureTech Health's price analysis, check to measure PureTech Health's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PureTech Health is operating at the current time. Most of PureTech Health's value examination focuses on studying past and present price action to predict the probability of PureTech Health's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PureTech Health's price. Additionally, you may evaluate how the addition of PureTech Health to your portfolios can decrease your overall portfolio volatility.